Search results
As a mid-sized global biopharmaceutical company, Ipsen improves patients’ lives through research, innovation and the development of transformative medicines in Oncology, Rare Disease and Neuroscience. WHAT WE DO.
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.
Learn about Ipsen, a global pharma company that aims to prolong patients’ lives, improve health outcomes and create a positive impact for patients and society.
As a mid-sized global biopharmaceutical company, Ipsen improves people’s lives through research, innovation and the development of transformative medicines in Oncology, Rare Disease and Neuroscience.
We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.
Ipsen India operates out of our state-of-the-art manufacturing plant in Kolkata, as well as regional offices that provide support to our customers throughout the country and surrounding regions. +91 20 2553 5045
Ipsen Technologies Pvt Ltd is a 100% owned Indian subsidiary of Ipsen International, Germany. Ipsen, with wholly owned units in Germany, USA, China, Japan and India, not only enjoys the widest...
Ipsen India exemplifies the power of collaboration in Ipsen’s journey towards growth and excellence. The history of Ipsen India began in 1982 when a licensing agreement was formed between Ipsen International in Germany and a Kolkata based industrial company.
Ipsen India’s Atmosphere Technology Business continues to trend up, achieving 27 percent YOY sales growth for Atmosphere Furnaces in 2022.
Apr 24, 2024 · Ipsen Pharma. PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024....
